Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Lesaffre invests in Intralytix, a US biotechnology company
Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based prod
Intralytix was recently given a positive #LuxTake by Lux Research
In the most recent report, Lux rated Intralytix as superior in 8 out of 10 categories used to rank the competitive companies
Intralytix phage-based Shigella tech backed by FDA
Intralytix Inc's product targeting Shigella has received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).
Intralytix, Inc. and BioPhage Therapeutics Limited partner to develop topical bacteriophage treatments of human wounds infected with S. aureus.
Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.